AstraZeneca to present Farxiga CV data at ACC 2019

AstraZeneca to present data evaluating CV effects of Farxiga.
These data are the first sub-analyses from the Phase III DECLARE-TIMI 58 trial for Farxiga.

Data evaluating the cardiovascular (CV) effects of Farxiga (dapagliflozin), including hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session on 16-18 March.

These data are the first sub-analyses from the Phase III DECLARE-TIMI 58 trial for Farxiga.

AstraZeneca will also present the latest results from the Brilinta (ticagrelor) Phase III TREAT trial in patients with the most dangerous form of heart attack, ST-segment elevation myocardial infarction (STEMI). The company will also present a new heart failure analysis from CVD-REAL, the first large real-world evidence study of its kind evaluating the risk of all-cause death and hHF in patients with T2D receiving treatment with a SGLT2 inhibitor (SGLT2i), including Farxiga.

Joris Silon, Senior Vice President, Cardiovascular, Renal and Metabolism, BioPharmaceuticals, said: “AstraZeneca is committed to addressing some of the most pressing health problems faced by patients with cardiovascular and metabolic diseases, by identifying and mitigating specific risks.

“This is particularly important in reducing the prevalence and burden of heart failure. This disease affects nearly 64 million people globally, and is an early and frequent complication in patients with type-2 diabetes.”